Artivion stock slides 23% after Endospan acquisition plan and lower outlook
Updated
Updated · MarketWatch · May 7
Artivion stock slides 23% after Endospan acquisition plan and lower outlook
7 articles · Updated · MarketWatch · May 7
Shares fell to $27.30 after hours as Artivion agreed to buy Endospan for $175 million cash, or about $135 million net, after FDA approval for its Nexus Aortic Arch System.
The deal, expected to close in the second quarter, could include up to $200 million in contingent payments and adds three premarket-approval programmes to Artivion's aortic arch pipeline.
Artivion also posted first-quarter adjusted earnings of 8 cents a share on $116.3 million revenue and cut 2026 revenue guidance to $480 million-$496 million from $486 million-$504 million.
After a 23% stock crash, is Artivion’s costly acquisition a visionary move or a reckless bet on a risky new device?
The FDA-approved Nexus device offers new hope, but is its high stroke risk and cost a price worth paying for patients?